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Abstract Levels of urinary albumin excretion that are below
theusuallimitofdetectionbyqualitativetesting,butareabove
normal levels (microalbuminuria; MA), can be readily
identified by simple measures, such as the urinary albumin
to creatinine ratio in untimed urine samples. Such measure-
ments, particularly when combined with assessment of
estimated glomerular filtration rate (eGFR), have utility as
biomarkers for enhanced risk of all-cause mortality, cardio-
vascular events, progressive chronic kidney disease, and end-
stage renal disease in diabetic and nondiabetic subjects.
However, it is controversial whether “isolated” MA (MA in
the absence of a clear reduction in eGFR, urine sediment
abnormalities, or structural renal disease) should be regarded
as kidney disease. Such MA could also be regarded as a
manifestation of a diffuse endothelial (microvascular) injury
and thereby collateral kidney damage. This article reviews the
current evidence concerning MA as a marker of kidney
disease or kidney damage.
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Introduction
Microalbuminuria (MA) was delineated many years ago to
describe the appearance of small quantities of albumin, too
little to detect by standard “dipstick” methods, in urine
samples from subjects with diabetes [1, 2]. According to
recent guidelines, MA may be defined as the urinary
excretion of 30–300 mg/d in a timed urine collection in
adults [3]. When spot urine samples are used, the recom-
mended definitions of MA are the excretion of 17–250 mg/g
of creatinine in men and 25–355 mg/g of creatinine in
women. This measurement is known as the urinary albumin
to creatinine ratio (UACR). The gender-associated differ-
ences in definition result from variation in daily creatinine
generation—females have lower creatinine generation than
males [4]. In addition, variations in the quantification of
albuminuria for these definitions of MA may need to be
applied to the elderly (who have greatly decreased creatinine
generation) or to excessively muscular individuals (who have
high creatinine generation) [3]. Urinary albumin concentra-
tion in untimed urinary collections may also be used to
define MA—values of 3–30 mg/dL generally are regarded as
fulfilling the definition. Albumin in urine is most often
measured by immuno-turbidimetry using antibodies reactive
with intact albumin. Alternatively, high-pressure liquid
chromatography can be used, but this method also measures
nonimmunologically reactive albumin and albumin frag-
ments, which yields higher values than immuno-turbidimetry
[5]. In general, MA corresponds to a “trace” reading on
dipstick testing of urine, but results depend on the degree of
urine concentration. Dye-impregnated strips that have en-
hanced sensitivity for albumin are also available [6]. Simple,
portable, “point-of-service” instruments that measure small
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The precise organ of urinary albumin remains somewhat
controversial. The dominant viewpoint is that albumin is
normally filtered by the glomeruli in small but significant
amounts, about 1 to 2 mg/min (~ 2 g/d), but the great
majority (99%) of filtered albumin is reabsorbed and
degraded by the proximal tubule, leaving less than about
5 μg/min (7 mg/d) to be excreted [8]. A minority view is
that larger amounts of albumin are filtered, as much as
200 g/d, but a retrieval pathway in the proximal tubule
reclaims the filtered albumin intact and delivers it to the
circulation, except for small amounts of intact and partially
or fully degraded albumin [9]. In pathologic states, the
glomeruli may become increasingly permeable to circu-
lating albumin by virtue of disturbances in endothelial cell
function, basement membrane abnormalities, or podocyte
(visceral epithelial cell) disorders. Currently, the focus is on
disturbances of endothelial or podocyte function as causes
of excessive albumin glomerular permeability, rather than
disturbances of basement membrane physiology [8]. Albu-
min is negatively charged at physiologic pH and may be
impeded in transglomerular passage by the anionic residues
in endothelial cell, glomerular basement membrane, or
podocyte [8]. However, the existence of a charge-selective
permeability barrier has been challenged [10]. A reduction
in proximal tubule reclamation or reabsorption of filtered
albumin can also cause albuminuria [9]. Finally, physico-
chemical alterations in the circulating albumin molecule
can affect its permeation through the glomerular capillary
wall, by altering the shape or possibly the electrical charge
[11]. Thus, the mechanisms underlying increased urinary
albumin excretion are complex and it is often difficult to
ascribe MA in specific patients to a unique pathophysio-
logic process; however, endothelial cell dysfunction, a
podocytopathy, or both seem to underlie most instances.
Nevertheless, it remains possible that alterations in proxi-
mal tubular function may contribute to albuminuria in some
circumstances, such as during poorly controlled glycemia in
diabetes mellitus. These considerations are important when
one attempts to relate albumin excretion rates to the
definition of kidney disease, because albuminuria arising
from diffuse endothelial cell injury (eg, in atherosclerosis
and hypertension) might best be regarded as a sign of a
systemic disease process, affecting many organs and systems,
rather than one originating in the kidneys. Alternatively,
albuminuria arising from a podocyte dysfunction could
legitimately be regarded as a manifestation of a kidney
disease. Regardless of the underlying mechanisms and
interpretation of the pathophysiologic meaning of albumin-
uria, important associations exist between the quantities of
albumin excreted in the urine and progressive chronic kidney
disease (CKD) and cardiovascular (CV) events.
Microalbuminuria: Association with Progressive
“Generic” CKD and CV Events
Microalbuminuria, as defined above, has been consistently
associated with an increased likelihood of progression of
generic CKD to more advanced stages or even to end-stage
renal disease (ESRD) in large epidemiologic studies [12￿￿,
13￿, 14￿￿, 15]. These observations have been used to justify
the inclusion of MA in the definition of generic CKD in the
original classification schema of the Kidney Disease
Outcome Quality Initiative (KDOQI) of the National
Kidney Foundation (NKF) in 2002 [3]. Indeed, the
presence of MA (defined as UACR of 30–299 mg/g
creatinine without gender or age adjustments) as the sole
reason for diagnosing generic CKD accounted for 90% of
those with stage 1 CKD and 87% of those with stage 2
CKD in the US National Health and Nutrition Examination
Survey (NHANES) conducted from 1999 to 2004 [16]. In
this cohort (N=13,233), 6.8% had self-reported diabetes
and 27% had diagnosed hypertension. Thus, the great
majority of subjects designated as having stage 1 or 2 CKD
in NHANES had isolated MA (MA without a clear
reduction in estimated glomerular filtration rate [eGFR],
urine sediment changes, or structural kidney disease) as the
defining abnormality. It is natural to ask whether such
isolated MA is sufficient reason to designate a person as
having generic CKD.
As shown by a recent, very large, collaborative meta-
analysis (Chronic Kidney Disease Prognosis Consortium; N=
105,872 subjects), the hazard ratio (HR) for all-cause
mortality and cardiovascular mortality (adjusted for the
effects of age, ancestry, history of CV disease, systolic blood
pressure, diabetes, smoking, and total cholesterol concentra-
tion) rises progressively above a UACR of about 10 mg/g
[17￿￿]. In subjects with normal renal function (eGFR=90–
104 mL/min/1.73 m
2), the HR for CV mortality is 1.63 at a
UACR of 10–29 mg/g, 1.82 at 30–299 mg/g, and 4.77 at
greater than 300 mg/g. A decrease in eGFR magnifies the
effect of an increased UACR on both all-cause and CV
mortality, especially at an eGFR of 45 mL/min/1.73 m
2 or
lower. Thus, there is little or no doubt that increased albumin
exertion, even below the conventional MA range, is
associated with an increased likelihood for mortality, both
all-cause and CV-related. The causal direction for this
association cannot be determined from this epidemiologic
data. Is elevated albumin excretion a biologic marker of
underlying systemic disease (eg, cancer, atherosclerosis), or
is it somehow involved in the causal pathway for fatal
events, including CV disease?
Similarly, the risk of developing a progressive form of
CKD is linked somehow to the presence of elevated
albumin exertion. A large, community-based study from
Alberta, Canada, (N=920,875) showed that subjects with
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1.73 m
2, average age 46 years) and MA had event rates of
ESRD of 1.5 and doubling of serum creatinine of 2.8 times
those of subjects with “normal” albumin excretion
(<30 mg/g UACR) [14￿￿]. Absolute events rates were
low: 0.06 per 1000 person-years of follow-up for ESRD in
the normo-albuminuric group versus 0.09 per 1000 patient-
years for the MA group. A lowered eGFR magnified the
effect of MA on the occurrence of ESRD and doubling of
the serum creatinine, especially at levels below 45 mL/min/
1.73 m
2. In another community-based study (N=65,589
adults; 3.3% diabetic; average age, 50.1 years), researchers
noted that the likelihood of developing (and surviving long
enough) to receive treatment for ESRD among subjects
with MA and eGFR≥60 mL/min/1.73 m
2 was 27 times that
of subjects with normo-albuminuria and similar eGFR
levels [13￿]. A reduced eGFR greatly magnified the effect
of MA on risk for ESRD. Subjects with an eGFR less than
60 mL/min/1.73 m
2 and MA had a 5.4-fold to 81-fold
increased risk of ESRD compared to those with an eGFR≥
60 mL/min/1.73 m
2, depending on the degree of decrease in
eGFR. Thus, the addition of MA to eGFR greatly enhances
the ability to detect and quantify risk of progressive CKD,
particularly when eGFR is less than 60 mL/min/1.73 m
2.
These observations call for a revision of the 2002 version of
the KDOQI-NKF classification schema for CKD that does
not include albuminuria for diagnosis of stage 3 or above
CKD [3]
Taken together, these findings from epidemiologic
studies using large databases strongly support the view
that MA needs to be considered as a “biomarker” of
adverse outcomes, even among those subjects with
normal or nearly normal renal function. However, the
strength of this association between MA and outcomes
may vary by subject age and underlying disease (eg,
diabetic or nondiabetic) or by concomitant illness
known to influence albumin excretion rates (eg, obesi-
ty). For example, in the aforementioned meta-analysis
conducted by the Chronic Kidney Disease Prognosis
Consortium [17￿￿], the pooled estimates of fully adjusted
HR for CV mortality tended to be higher in those
younger than 65 years of age compared to those older
than 65 years with apparently equivalent degrees of MA.
An analysis of the impact of MA on outcomes in the old-
old (>75 years of age) has not been conducted; however,
as stated above, UACR has a tendency to increase with
normal aging, predominantly because of the effects of
sarcopenia on creatinine generation, not necessarily
because of an absolute increase in albumin excretion
with aging. Furthermore, the association of MA with
adverse outcomes in subjects with normal or nearly
normal renal function (eGFR≥60 mL/min/1.73 m
2), after
adjustment for the effects of aging may simply reflect the
overall burden of atherosclerotic vascular disease in this
group of subjects. As recently pointed out by Kalaitzidis
and Bakris [18], untangling the influences of metabolic
disturbances and hypertension in diabetic and nondiabet-
ic subjects with concomitant MA can be problematical. It
is still uncertain if MA is an integral part of the
pathophysiologic pathways for CV disease or simply a
bystander.
Microalbuminuria: Association with Progression
of “Specific” CKD
The sine qua non of “specific” forms of CKD in which MA
is present is that of diabetes mellitus. Indeed, the concept of
MA arose from studies of the natural history of diabetic
nephropathy during the period 1981 to 1982 [1, 2]. Shortly
after its initial description in type 1 diabetes, MA was
believed to be a harbinger of overt diabetic nephropathy
and progressive CKD. We now recognize that MA in type 1
diabetes is a dynamic process with frequent spontaneous
regression to normo-albuminuria [19, 20]. We also recog-
nize the wide array of extra-renal factors that can influence
albumin excretion, such as obesity, age, gender, distant
inflammation, and certain drugs (eg, rosuvastatin) [21￿, 22,
23]. Furthermore, studies done at the Joslin Clinic over
many years indicate that more advanced stages of CKD are
not uniformly associated with progression of MA to overt
microalbuminuria [19, 24]. Pathologic abnormalities indic-
ative of diabetic nephropathy (eg, increased mesangial
fractional volume) precede the development of MA, and
very clearly renal functional decline can occur in the
absence of MA, at least in type 1 diabetes [25]. Type 2
diabetes may be another story, because the relationship of
MA and renal functional decline is not as well studied or
understood as in type 1 diabetes, and this relationship is
confounded by concomitant accelerated atherosclerotic
macrovascular disease. Nevertheless, several studies
showed that progression of type 2 diabetes can occur in
the absence of MA [21￿, 22–26]. Interventions designed
specifically to reduce MA have not consistently shown a
reduction of later progression to advanced CKD or ESRD.
Some recent interventional trials (eg, the Avoiding Cardio-
vascular Events through Combination Therapy in Patients
Living with Systolic Hypertension [ACCOMPLISH] trial)
involving type 2 diabetic subjects showed that the change
in albumin excretion rates can be disassociated from risk of
progression to ESRD under the influence of combined
renin-angiotensin system blockade and calcium channel
antagonism [21, 27￿]. Taken together, these observations in
type 1 and type 2 diabetes suggest, but do not prove, that
MA may not be a reliable marker of kidney disease or its
progression.
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Among patients with well-established kidney disease (ie,
eGFR <45–50 mL/min/1.73 m
2), the magnitude of
albuminuria can be viewed as a marker of a more
progressive course and a more rapid loss of renal function
(a “risk marker” rather than a “risk factor”)f o rb o t h
diabetic and nondiabetic renal disease [28, 29]. This
finding may well be a manifestation of “lead-time bias,”
in that those with lower levels of albumin excretion have
disease in its earlier stages and thus a greater reserve of
functioning nephrons, whereas those with higher levels of
albuminuria have no reserves and with each loss of nephrons,
a corresponding decline in renal function becomes
evident. In this sense, the level of albumin excretion is
a relevant marker of kidney disease and risk of its
progression. A conundrum exists when renal function is
entirely or nearly normal: no overt structural renal
disease is evident, yet albumin excretion is elevated into
the MA range. Such patients might be described as
having “isolated” MA. No doubt this circumstance
somehow predisposes to, or is a marker of a predis-
position to, CV disease. The exact pathophysiologic
connection between isolated MA and CV disease is not
fully clarified. For example, albuminuria correlates with
parameters of aortic stiffness and carotid plaque forma-
tion but not with carotid intima-media thickness as a
surrogate for widespread atherosclerosis [30]. On the
other hand, MA does correlate with signs of altered
endothelial function, such as endothelium-dependent
vascular dilatation [31–33]; however, it is often difficult
to disentangle the effects of alterations in renal function
and concomitant metabolic and dyslipidemia states in
identifying direct relationships between MA and endothe-
lial dysfunction. Isolated MA may well be a biomarker of
widespread vascular injury and atherosclerotic burden. In
this sense, it is not measuring a “kidney disease” per se,
but only a secondary and indirect effect of a distant
disease process on kidney physiology. Although this
conclusion may appear to be semantic rather than reality-
based, it has immediate relevance for the diagnosis of
CKD using current classification schema (ie, KDOQI-
CKD). Stage 1 and 2 CKD in this schema cannot be
reliably distinguished on the basis of eGFR alone because
current creatinine-based eGFR formulas are imprecise.
Whether newer cystatin C–based formulas will correct this
deficiency remains to be seen; preliminary findings are
encouraging, but not uniformly so [34, 35]. Most cases of
stage 1 and 2 CKD are currently defined on the basis of
M A ,t y p i c a l l yi na ni s o l a t e df o r m .T h i sd e f i n i t i o ni su s e f u l
to stratify the eventual risk of CV events and all-cause
mortality; however, does it have the same utility for
defining the presence of and risk for progressive CKD and
eventual ESRD at all levels of eGFR and in all ages?
Current evidence suggests that the utility of MA in
predicting renal outcomes is most pronounced in those with
well-established kidney disease (eg, eGFR <45–50 mL/min/
1.73 m
2) and in younger subjects (eg, <65 years of age). In
my opinion, whether it is appropriate to regard isolated
MA as equivalent to kidney disease is still an open
question. A compromise position would be to regard this
laboratory finding as an indication of kidney “damage”
rather than giving it the more ominous label of “disease.”
This issue is not trivial—about 30% of those diagnosed
as having CKD in epidemiologic studies have their
kidney disease identified by the finding of MA and
eGFR≥60 mL/min/1.73 m
2 in the absence of a self-
reported diagnosis of diabetes.
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